Bupropion for Patients With Obsessive-Compulsive Disorder: An Open-Label, Fixed-Dose Study
J Clin Psychiatry 2005;66(2):228-230
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: In the present study, we examined the
efficacy of bupropion for patients with obsessive-compulsive
Method: Twelve patients with OCD according to
DSM-IV criteria were included in an open trial with bupropion,
maximum dosage 300 mg per day, during 8 weeks. The primary
efficacy parameter was the Yale-Brown Obsessive Compulsive Scale
(YBOCS). A responder was defined by a reduction in score on the
YBOCS of >= 25%. Data were collected from February 2003 to
Results: An intent-to-treat analysis using the
last observation carried forward demonstrated that bupropion had
no mean effect on OCD symptoms (mean YBOCS decrease was 1.1 ±
9.6). Four patients improved, with a mean decrease on the YBOCS
of 31%, and 2 of them met responder rate criteria. Eight patients
experienced an exacerbation of OCD symptoms, with a mean increase
on the YBOCS of 21%.
Conclusion: Bupropion is not an effective
treatment for OCD, but the bimodal distribution of the effect
supports the notion that dopamine might be involved in the
pathophysiology of OCD.